Compare · CBAT vs TMO
CBAT vs TMO
Side-by-side comparison of CBAK Energy Technology Inc. (CBAT) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- CBAT operates in Miscellaneous, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $225.41B, about 2248.8x CBAT ($100.2M).
- Over the past year, CBAT is up 14.5% and TMO is up 11.5% - CBAT leads by 3.0 points.
- TMO has been more active in the news (6 items in the past 4 weeks vs 1 for CBAT).
- TMO has more recent analyst coverage (25 ratings vs 0 for CBAT).
- Company
- CBAK Energy Technology Inc.
- Thermo Fisher Scientific Inc
- Price
- $0.81-3.55%
- $469.57+0.63%
- Market cap
- $100.2M
- $225.41B
- 1M return
- -1.81%
- -4.31%
- 1Y return
- +14.48%
- +11.45%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 1
- 6
- Recent ratings
- 0
- 25
CBAK Energy Technology Inc.
CBAK Energy Technology, Inc., together with its subsidiaries, develops, manufactures, and sells lithium batteries in Mainland China, the United States, Israel, and internationally. Its products are used in various applications, including electric vehicles, such as electric cars, electric buses, and hybrid electric cars and buses; light electric vehicles that include electric bicycles, electric motors, and sight-seeing cars; and electric tools, energy storage, uninterruptible power supply, and other high power applications, as well as cordless power tools. The company was formerly known as China BAK Battery, Inc. and changed its name to CBAK Energy Technology, Inc. in January 2017. CBAK Energy Technology, Inc. was incorporated in 1999 and is based in Dalian, China.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest CBAT
- CBAK Energy Achieves 2nd in 26650/26700 and 3rd in 32140 Cylindrical Cell Shipments in China
- SEC Form 10-K filed by CBAK Energy Technology Inc.
- CBAK Energy Technology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- CBAK Energy Reports Fourth Quarter and Full Year 2025 Unaudited Financial Results
- CBAK Energy to Report Fourth quarter & Full year 2025 Unaudited Financial Results on Monday, March 30, 2026
- CBAK Energy Technology Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events
- SEC Form NT 10-K filed by CBAK Energy Technology Inc.
- SEC Form DEF 14A filed by CBAK Energy Technology Inc.
- SEC Form DEFA14A filed by CBAK Energy Technology Inc.
- CBAK Energy Technology Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
Latest TMO
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Thermo Fisher Scientific Reports First Quarter 2026 Results
- AI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost Advantages
- Thermo Fisher Scientific Expands Global Biobank Leadership Through Strategic Collaboration with PRECISE-SG100K Singapore to Advance Population-Scale Proteomics
- SEC Form DEFA14A filed by Thermo Fisher Scientific Inc
- SEC Form DEF 14A filed by Thermo Fisher Scientific Inc
- Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, April 23, 2026
- SEC Form 4 filed by Sperling Scott M
- SEC Form 4 filed by Keith R. Alexandra
- SEC Form 4 filed by Lynch Karen S